BioSpace News Archive

Rakuten Medical, Inc. announced that data from a phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma was accepted for publication in Head and Neck and published online on October 9th, 2021.

Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter ended September 30, 2021 after the market close on Wednesday, November 10, 2021.

Corcept Therapeutics Incorporated announced it will report third quarter financial results and provide a corporate update on November 3, 2021.

Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS), today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. (Angel Pharma), has been approved by the Center for Drug Evaluation (CDE) of the China National Medical Products Administration (NMPA) to initiate a Phase 1/1b clinical trial of Corvus’ small molecule ITK inhibitor CPI-818 for the treatment of relapsed/refractory T-cell lymphomas (TCL) in China.

Align Technology, Inc. announced the findings of a multi-center clinical study, “Reflected near-infrared light versus bite-wing radiography for the detection of proximal caries: a multicenter prospective clinical study conducted in private practices,” published in the peer-reviewed Journal of Dentistry.

Orthofix Medical Inc., a global medical device company with a spine and orthopedics focus, announced that it plans to release financial results for the third quarter 2021 before market open on Friday, November 5, 2021.

Invacare CorporationInvacare Corporation reported results for the quarter ended September 30, 2021.

Biotecnica, a leading manufacturer of peptones has launched a new line of low endotoxin peptones that do not require ultrafiltration.

Volumetric, announced today it has entered into an agreement to be acquired by 3D Systems (NYSE:DDD) in a deal structured as $45 million closing payment, with up to $355 million additional opportunity linked to a series of milestone earnouts upon the attainment of significant steps in the demonstration of human applications.

Checkmate Pharmaceuticals, Inc. today announced that Alan Fuhrman has been appointed as interim President and CEO.